Browsing Tag
Johnson & Johnson
102 posts
Johnson & Johnson discontinues JNJ-5939 after DUPLEX-AD trial misses efficacy threshold in atopic dermatitis
Johnson & Johnson has discontinued JNJ-5939 in atopic dermatitis after interim trial results fell short of efficacy benchmarks. Find out what this means for the pipeline.
Halda Therapeutics joins Johnson & Johnson in $3bn cancer drug platform deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B. Find out why its RIPTAC platform could reshape prostate and solid tumor cancer treatment.
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Is Alvotech about to reshape Europe’s anti-TNF market with its Simponi biosimilar?
Alvotech and STADA launch Europe’s first Simponi biosimilar, Uzpruvo. Find out how this shifts competition in the €1B+ anti-TNF therapy market.
Can J&J’s five-minute NSCLC injection disrupt the EGFR frontline market long ruled by osimertinib?
Johnson & Johnson’s five-minute NSCLC injection RYBREVANT FASPRO wins FDA approval. Learn how this subcutaneous delivery could reshape EGFR frontline therapy.
Johnson & Johnson expands AKEEGA’s reach with FDA nod in BRCA2-mutated metastatic castration-sensitive prostate cancer
Johnson & Johnson’s AKEEGA secures FDA approval for BRCA2-mutated prostate cancer, reshaping early-stage treatment and signaling a shift toward genomic-first therapy.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Johnson & Johnson fortifies urologic oncology pipeline with compelling Inlexzo results
Johnson & Johnson's new data show Inlexzo delivers strong one-year disease-free survival. Find out how it could shift bladder cancer care.
XOMA Royalty completes LAVA Therapeutics acquisition in push to strengthen bispecific antibody pipeline
Find out how XOMA Royalty’s acquisition of LAVA Therapeutics strengthens its oncology royalty portfolio and expands its partnered bispecific antibody programs.
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.